Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.
Hologic, Inc. reports corporate-status and women’s health medical-technology developments following its acquisition by funds managed by Blackstone and TPG, which established Hologic as a private company. Its news has covered the completed transaction, governance changes, operating and financial results, and capital-structure matters tied to the former Nasdaq-listed common stock.
Company updates also describe Hologic’s diagnostics and cervical-health portfolio, including the Aptima HPV Assay, ThinPrep Pap Test and Genius Digital Diagnostics System, as well as public-health initiatives such as the Hologic Global Women’s Health Index and screening-awareness campaigns.
Hologic (NASDAQ: HOLX) has received FDA authorization for its Aptima® SARS-CoV-2 assay, allowing testing for asymptomatic individuals. This follows a previous authorization for the Panther Fusion® SARS-CoV-2 assay. The CDC now recommends testing for individuals with recent contact with infected persons, enhancing the importance of Hologic's testing capabilities. The Aptima tests deliver results in approximately three hours and can process over 1,000 tests daily. Hologic has produced tens of millions of assays, securing a substantial role in global COVID-19 testing supply.
Hologic, Inc. (HOLX) has launched a multi-year initiative to reduce breast cancer screening disparities among Black women, partnering with the Black Women’s Health Imperative (BWHI) and RAD-AID. The program, introduced during Breast Cancer Awareness Month, aims to promote annual mammograms starting at age 40 and enhance access to screening technology in underserved communities. Research highlights that Black women face a 40% higher risk of dying from breast cancer. The effort addresses urgent needs exacerbated by COVID-19, seeking to mobilize resources to improve healthcare access.
Hologic, Inc. (Nasdaq: HOLX) has received Emergency Use Authorization (EUA) from the FDA for its Panther Fusion® SARS-CoV-2 assay, enabling testing for asymptomatic individuals. This is the first high-throughput molecular diagnostic test authorized for this purpose, aimed at identifying early infections and aiding in the reopening of schools and workplaces. The CDC's guidance supports testing for those exposed to the virus. Hologic plans to submit clinical evaluation results for further validation of its testing capabilities.